Pharma major Lupin Limited (Lupin) has announced the launch of Levothyroxine Sodium Tablets USP, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin's Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc's Synthroid® Tablets. It is indicated for:
- Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism
- Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer
Levothyroxine Sodium Tablets, 25 meg, SO meg, 75 meg, 88 meg, 100 meg, 112 meg, 125 meg, 137 meg, 150 meg, 175 meg, 200 meg, and 300 meg had an annual sales of approximately USD 2.5 billions in the U.S (IQVIA MAT January 2019).
Shares of LUPIN LTD. was last trading in BSE at Rs.755 as compared to the previous close of Rs. 755.3. The total number of shares traded during the day was 85537 in over 2576 trades.
The stock hit an intraday high of Rs. 759.2 and intraday low of 748. The net turnover during the day was Rs. 64378990.